Who are Tepezza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CERITINIB, TEPEZZA, Teprotumumab N01, insulin eye drops, TEPEZZA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teprotumumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tepezza — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tepezza (TEPROTUMUMAB) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]. Area: Metabolic.

marketed Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] IGF-1R Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Tepezza (TEPROTUMUMAB) — Horizon Therapeutics Ireland. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tepezza TARGET	TEPROTUMUMAB	Horizon Therapeutics Ireland	marketed	Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]	IGF-1R	2020-01-01
CERITINIB	CERITINIB		marketed	Kinase Inhibitor [EPC]	ALK, IGF-1R, InsR, ROS1	2014-01-01
TEPEZZA	TEPEZZA	Amgen	marketed	IGF-1R inhibitor monoclonal antibody	IGF-1R (Insulin-like Growth Factor-1 Receptor)
Teprotumumab N01	Teprotumumab N01	Innovent Biologics (Suzhou) Co. Ltd.	marketed	IGF-1 receptor antagonist monoclonal antibody	IGF-1R (Insulin-like Growth Factor-1 Receptor)
insulin eye drops	insulin eye drops	Hotel Dieu de France Hospital	marketed	Topical peptide therapeutic	Insulin receptor (IGF-1R cross-reactivity possible)
TEPEZZA	TEPROTUMUMAB-TRBW	HORIZON THERAPEUTICS IRELAND	marketed	Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]	Insulin-like growth factor 1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] class)

HORIZON THERAPEUTICS IRELAND · 1 drug in this class
Horizon Therapeutics Ireland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tepezza — Competitive Intelligence Brief. https://druglandscape.com/ci/teprotumumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing